Latest News for: cd47
Edit
Hastings Tribune
30 Jan 2026
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept
- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – ... .
Edit
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination ...
Nasdaq Globe Newswire 30 Jan 2026
- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – ... .
Edit
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer (Form 8-K) (ALX Oncology Holdings Inc)
Public Technologies 30 Jan 2026
New Data Demonstrate CD47 Expression Level Helps Predict Response to ... "These new findings support a CD47-dependent, HER2-driven biology for evorpacept," said Barbara Klencke, M.D., Chief Medical Officer at ALX Oncology.
Edit
Hastings Tribune
08 Jan 2026
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor
Edit
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
Nasdaq Globe Newswire 08 Jan 2026- 1